[1] WHO. Novel coronavirus—China. Jan 12. 2020. http://www.who.int/csr/don/12-january–2020-novel-coronavirus-china/en/ (accessed Jan 19, 2020)
[2] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet,2020,395:497–506. DOI: 10.1016/S0140–6736(20)30183–5.
[3] Hui D S, I A E, Madani T A, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis,2020,91:264–266. DOI: 10.1016/j.ijid.2020.01.009
[4] Zhou P, Yang X, Wang X, et al. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. bioRxiv,2020. DOI:10.1101/2020.01.22.914952
[5] Wu Z, Mcgoogan J M. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID–19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA,2020. DOI: 10.1001/jama.2020.2648
[6] Wang C, Horby P W, Hayden F G, et al. A novel coronavirus outbreak of global health concern. Lancet,2020,395(10223):470–473. DOI: 10.1016/S0140–6736(20)30185–9
[7] Hamming I, Timens W, Bulthuis M L, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol,2004,203(2):631–637. DOI: 10.1002/path.1570
[8] Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA,2020. DOI: 10.1001/jama.2020.1585
[9] Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID–19 in Wuhan, China: a retrospective cohort study. Lancet,2020,395(10229):1054–1062. DOI: 10.1016/S0140–6736(20)30566–3
[10] Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet,2020,395(10223):507–513. DOI: 10.1016/S0140–6736(20)30211–7
[11] New coronavirus pneumonia prevention and control program (6th ed.) (in Chinese). 2020. (http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2/files/b218cfeb1bc54639af227f922bf6b817.pdf).
[12] 2018 Chinese Guidelines for Prevention and Treatment of Hypertension-A report of the Revision Committee of Chinese Guidelines for Prevention and Treatment of Hypertension. J Geriatr Cardiol,2019,16(3):182–241. DOI: 10.11909/j.issn.1671–5411.2019.03.014
[13] Wrapp D, Wang N, Corbett K S, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science,2020,367(6483):1260–1263. DOI: 10.1126/science.abb2507
[14] Yin Y, Wunderink R G. MERS, SARS and other coronaviruses as causes of pneumonia. Respirology,2018,23(2):130–137. DOI: 10.1111/resp.13196
[15] Song Z, Xu Y, Bao L, et al. From SARS to MERS, Thrusting Coronaviruses into the Spotlight. Viruses,2019,11(1). DOI: 10.3390/v11010059
[16] Chen Z, Hu J, Zhang Z, et al. Caution: The clinical characteristics of COVID–19 patients at admission are changing. bioRixv,2020. DOI.org/10.1101/2020.03.03.20030833
[17] [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID–19) in China]. Zhonghua Liu Xing Bing Xue Za Zhi,2020,41(2):145–151. DOI: 10.3760/cma.j.issn.0254–6450.2020.02.003
[18] Jaillon S, Berthenet K, Garlanda C. Sexual Dimorphism in Innate Immunity. Clin Rev Allergy Immunol,2019,56(3):308–321. DOI: 10.1007/s12016–017–8648-x.
[19] Zhang J, Dong X, Cao Y, et al. Clinical characteristics of 140 patients infected with SARSCoV–2 in Wuhan, China. Allergy,2020. DOI: 10.1111/all.14238
[20] Xintian X, Ping C, Jingfang W, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Science China Life Sciences,2020:1–4. DOI: 10.1007/s11427–020–1637–5
[21] Zhao Y, Zhao Z, Wang Y, et al. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. bioRixv,2020. DOI: https://doi.org/10.1101/2020.01.26.919985
[22] Li W, Moore M J, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature,2003,426(6965):450–454. DOI: 10.1038/nature02145.
[23] Zhou P, Yang X L, Wang X G, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature,2020,579(7798):270–273. DOI: 10.1038/s41586–020–2012–7.
[24] Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med,2005,11(8):875–879. DOI: 10.1038/nm1267.
[25] Yang J K, Lin S S, Ji X J, et al. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol,2010,47(3):193–199. DOI: 10.1007/s00592–009–0109–4.
[26] Yisireyili M, Uchida Y, Yamamoto K, et al. Angiotensin receptor blocker irbesartan reduces stress-induced intestinal inflammation via AT1a signaling and ACE2-dependent mechanism in mice. Brain Behav Immun,2018,69:167–179. DOI: 10.1016/j.bbi.2017.11.010.
[27] Simoes E S A, Silveira K D, Ferreira A J, et al. ACE2, angiotensin-(1–7) and Mas receptor axis in inflammation and fibrosis. Br J Pharmacol,2013,169(3):477–492. DOI: 10.1111/bph.12159
[28] de Wit E, van Doremalen N, Falzarano D, et al. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbio,2016,14(8):523–534. DOI: 10.1038/nrmicro.2016.81